🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

LifeMD, Inc. LFMD R2K

Healthcare · Health Information Services · United States
https://lifemd.com

LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.

READ MORE ›
$4.28
-64.95% 1Y

Market & Price

Market Cap
$206.99M
Current Price
$4.28
High / Low (52W)
$15.06 / $2.64
Beta
2.02

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
8.31
PEG Ratio
-
Book Value
$0.32
Price to Book
13.54
P/S
1.07
EV/EBITDA
-12.50
Dividend Yield
-

Profitability & Returns

ROCE
-30.60%
ROE
-
ROA
-13.41%
Profit Margin
2.93%
Op Margin
-17.80%
EPS (Latest Qtr)
$-0.20
EPS (TTM)
$-0.44

Balance Sheet & Liquidity

Debt/Equity
0.41
Quick Ratio
0.89
Current Ratio
1.04
Debt
$6.17M
Total Assets
$70.41M
Current Assets
$51.83M
Working Capital
$10.26M

Ownership

Promoter Holding
14.47%
Chg in Prom Hold
-
FII / Inst Holding
37.19%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$178.69M
Total Revenue (TTM)
$193.33M
EBITDA
$-14.30M
Free Cash Flow
$-4.16M
Operating Cash Flow
$8.10M
Shares Outstanding
48.36M
Gross Margin
86.81%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
17.69%
Profit 5Y
43.84%
Revenue (YoY)
-1.40%
Earnings (YoY)
-

PROS

  • Compounding revenue at 17.7% over 5 years.
  • Profit CAGR of 43.8% over 5 years.

CONS

  • Trading 71.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 LFMD LifeMD, Inc. R2K 4.28 - $206.99M - -30.60% - 17.69% 43.84%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ----------------2.70M2.70M3.13M4.30M9.09M11.01M18.20M22.31M24.95M29.04M30.46M31.41M33.13M35.95M38.61M44.14M50.66M--50.89M62.22M60.17M7.08M50.16M
Cost of Revenue -----------------------------------8.14M7.43M7.41M4.23M5.93M
Gross Profit 52.31K143.34K127.45K93.86K214.06K187.85K205.90K303.09K526.27K996.23K79.73K474.99K1.52M1.25M1.50M2.06M1.99M2.04M2.45M2.97M7.40M9.33M14.99M18.19M19.85M23.79M25.82M26.70M28.91M31.40M33.83M39.54M45.64M--42.75M54.79M52.76M2.85M44.24M
Operating Expenses -----------------------------------43.93M55.69M54.73M9.07M53.17M
Operating Income -168.67K-177.64K-75.38K-132.94K7.83K-17.17K17.94K-105.10K-153.63K-207.70K-401.79K-380.30K-273.57K-279.31K-938.45K-438.63K-563.37K-833.16K-973.71K-1.74M-3.22M-20.53M-11.92M-16.13M-12.59M-13.11M-12.90M-7.07M-2.85M-4.90M-4.57M-6.17M-6.31M---1.18M-906.77K-1.97M-6.22M-8.93M
EBITDA -----------------------------------509.69K2.88M-133.33K-6.22M-6.93M
Interest Expense ---------------------------------558.60K-626.27K663.03K262.46K-190.79K-
Pretax Income ------------------------------------1.65M-1.57M-3.39M-6.03M-8.87M
Tax Provision ----------------------------------169.48K0-169.13K-123.41K0
Net Income -139.37K-140.94K-71.50K-103.90K1.67K-21.03K8.12K-62.05K-199.98K-226.65K-1.04M737.49K-679.06K627.28K-1.05M-548.98K-663.75K-818.10K-943.80K-2.39M-3.38M-20.62M-11.60M-16.83M-14.35M-13.30M-13.02M-7.28M-4.01M-6.73M-6.12M-6.77M-6.88M---183.78K-2.07M-3.81M19.96M-8.87M
Diluted EPS ----31,363,306.0030,650,000.0030,650,000.0032,010,375.00-0.01-0.01-0.02-0.02-----------------------0.02-0.06-0.100.41-0.20

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ------42.52K12.47M37.29M-119.03M152.55M154.82M194.06M
Cost of Revenue ----------18.67M18.90M21.44M27.71M
Gross Profit 473.87K627.06K541.31K971.09K3.29M2.66M6.33M9.94M28.43M-100.37M133.65M133.38M166.34M
Operating Expenses ----------140.05M148.14M153.79M174.01M
Operating Income -540.02K-546.41K-530.88K-262.22K-1.17M-1.23M-2.06M-2.89M-57.82M--39.69M-14.49M-20.40M-7.67M
EBITDA -----------35.92M-7.89M-14.21M-1.52M
Interest Expense ------------2.18M1.36M
Pretax Income -----------44.66M-17.41M-22.58M-10.19M
Tax Provision ----------360.70K428.00K598.00K45.72K
Net Income -445.65K-268.26K-460.49K-61.99K-1.11M-1.21M-1.24M-3.14M-58.65M--45.54M-20.60M-21.41M14.35M
Diluted EPS -----0.03-0.03-----1.57-0.70-0.530.25
R&D Expense ---23.93K----------

Compounded Sales Growth

5 Years:17.69%
1 Year:-1.40%

Compounded Profit Growth

5 Years:43.84%
1 Year:-

Stock Price Performance

1 Year:-64.95%
6 Months:+8.91%
3 Months:+60.30%
1 Month:-3.39%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2011Sep 2012Dec 2012Dec 2013Dec 2014Sep 2015Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --369.69K551.45K175.22K-448.47K789.82K1.26M2.62M3.45M13.40M-25.67M58.48M76.10M70.41M
Current Assets -------------11.31M42.60M52.37M51.83M
Cash & Equivalents 33.50K163.18K98.93K155.06K75.50K73.86K232.98K182.56K141.38K180.09K1.11M9.18M-3.96M33.15M32.65M36.79M
Inventory -------------3.70M2.76M2.80M2.77M
Receivables -------------2.83M5.28M10.46M9.31M
Total Liabilities --234.70K355.96K314.72K-267.48K-640.97K1.80M4.58M14.22M-32.97M52.91M83.65M47.25M
Current Liabilities --187.10K325.56K301.52K-267.48K1.15M640.97K1.19M3.98M13.93M-31.37M34.78M67.40M41.57M
Long Term Debt --------------17.93M9.89M-
Total Debt -------------4.13M18.93M24.93M6.32M
Total Equity -282.98K-135.00K195.49K-139.50K-100.08K-355.17K881.92K897.70K-988.18K-2.30M--6.83M3.51M-9.08M23.16M
Shares Outstanding -------------31.55M38.36M42.29M46.76M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -229.73K-259.07K33.44K-295.12K-407.91K-817.22K-905.52K251.41K-12.13M--22.94M8.82M17.51M8.28M
Investing Cash Flow ------141.44K-100.00K-798.14K--13.91M-8.73M-11.54M6.91M
Financing Cash Flow 295.15K315.20K-113.00K325.35K357.49K776.03K802.79K775.12K21.00M--528.20K29.10M-4.12M-13.41M
Capital Expenditure -----------12.89M-8.73M-8.20M-9.52M
Free Cash Flow -----------35.83M86.95K9.31M-1.24M
Net Change in Cash -----------37.37M29.19M1.86M1.78M
Share Buybacks -----76.65K-------270.00K
Dividends Paid ---------871.48K3.11M3.11M3.11M3.11M

Ratios (Annual)

Figures in %.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------14,883.9%79.7%76.2%-84.3%87.6%86.2%85.7%
Operating Margin % -------4,836.3%-23.2%-155.0%--33.3%-9.5%-13.2%-4.0%
Net Margin % -------2,918.6%-25.2%-157.3%--38.3%-13.5%-13.8%7.4%
ROE % -330.1%-137.2%330.1%-61.9%311.8%-136.7%-138.2%317.5%2,547.8%-666.7%-587.6%235.7%62.0%
ROCE % -295.7%-241.9%420.3%-144.9%324.7%-197.2%-144.4%546.0%10,920.8%-695.2%-61.1%-234.6%-26.6%

Shareholding Pattern

Insiders
14.47%
Institutions
37.19%
Public Float
43.48%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 5.81% 2.81M $12.02M
2 Vanguard Capital Management LLC 3.44% 1.66M $7.12M
3 Royce & Associates LP 2.48% 1.20M $5.14M
4 Renaissance Technologies, LLC 2.31% 1.12M $4.79M
5 State Street Corporation 2.22% 1.08M $4.60M
6 Federated Hermes, Inc. 2.11% 1.02M $4.36M
7 Geode Capital Management, LLC 2.11% 1.02M $4.36M
8 Prescott Group Capital Management, L.L.C. 1.85% 895.42K $3.83M
9 Brc Group Holdings, Inc. 1.80% 871.58K $3.73M
10 Susquehanna International Group, LLP 0.96% 465.19K $1.99M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for LFMD

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks